uracil has been researched along with Angina, Unstable in 10 studies
2,4-dihydroxypyrimidine: a urinary biomarker for bipolar disorder
Angina, Unstable: Precordial pain at rest, which may precede a MYOCARDIAL INFARCTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In patients with type 2 diabetes and recent acute coronary syndromes, alogliptin did not increase the risk of heart failure outcomes." | 9.20 | Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. ( Bakris, GL; Cannon, CP; Cushman, WC; Fleck, PR; Kupfer, S; Lam, H; Mehta, CR; Menon, V; Perez, AT; White, WB; Wilson, C; Zannad, F, 2015) |
| "In patients with type 2 diabetes and recent acute coronary syndromes, alogliptin did not increase the risk of heart failure outcomes." | 5.20 | Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. ( Bakris, GL; Cannon, CP; Cushman, WC; Fleck, PR; Kupfer, S; Lam, H; Mehta, CR; Menon, V; Perez, AT; White, WB; Wilson, C; Zannad, F, 2015) |
| "We randomly assigned patients with type 2 diabetes and either an acute myocardial infarction or unstable angina requiring hospitalization within the previous 15 to 90 days to receive alogliptin or placebo in addition to existing antihyperglycemic and cardiovascular drug therapy." | 5.17 | Alogliptin after acute coronary syndrome in patients with type 2 diabetes. ( Bakris, GL; Bergenstal, RM; Cannon, CP; Cushman, WC; Fleck, PR; Heller, SR; Kupfer, S; Mehta, CR; Nissen, SE; Perez, AT; White, WB; Wilson, C; Zannad, F, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 10 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| White, WB | 3 |
| Cannon, CP | 2 |
| Heller, SR | 1 |
| Nissen, SE | 1 |
| Bergenstal, RM | 1 |
| Bakris, GL | 2 |
| Perez, AT | 2 |
| Fleck, PR | 2 |
| Mehta, CR | 2 |
| Kupfer, S | 2 |
| Wilson, C | 2 |
| Cushman, WC | 2 |
| Zannad, F | 3 |
| Lim, GB | 1 |
| Greenhill, C | 1 |
| Standl, E | 1 |
| Doggrell, SA | 1 |
| Dimmitt, SB | 1 |
| Gallwitz, B | 1 |
| Nitschmann, S | 1 |
| Violini, R | 1 |
| Vigili de Kreutzenberg, S | 1 |
| Menon, V | 1 |
| Lam, H | 1 |
| Derosa, G | 1 |
| Maffioli, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Cardiovascular Outcomes Following Treatment With Alogliptin in Addition to Standard of Care in Subjects With Type 2 Diabetes and Acute Coronary Syndrome[NCT00968708] | Phase 3 | 5,380 participants (Actual) | Interventional | 2009-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Primary Major Adverse Cardiac Events were defined as a composite of cardiovascular death, nonfatal myocardial infarction and nonfatal stroke; these events were adjudicated by an independent cardiovascular endpoints committee. (NCT00968708)
Timeframe: From randomization until the adjudication cut-off date of May 31 2013 (maximum time on study was 41 months).
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 11.8 |
| Alogliptin | 11.3 |
Secondary MACE composite consisted of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or urgent revascularization due to unstable angina; these events were adjudicated by an independent cardiovascular endpoint committee. (NCT00968708)
Timeframe: From randomization until the adjudication cut-of date of May 31 2013 (maximum time on study was 41 months).
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 13.4 |
| Alogliptin | 12.7 |
3 trials available for uracil and Angina, Unstable
| Article | Year |
|---|---|
Alogliptin after acute coronary syndrome in patients with type 2 diabetes.
Topics: Aged; Angina, Unstable; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV | 2013 |
[The EXAMINE study].
Topics: Administration, Oral; Angina, Unstable; Biomarkers; Diabetes Mellitus, Type 2; Double-Blind Method; | 2014 |
Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathie | 2015 |
7 other studies available for uracil and Angina, Unstable
| Article | Year |
|---|---|
Diabetes: Cardiovascular safety of 'gliptin' therapy.
Topics: Adamantane; Angina, Unstable; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptides; Dipept | 2013 |
Pharmacotherapy: Cardiovascular safety of antihyperglycaemic drugs in patients with type 2 diabetes mellitus.
Topics: Adamantane; Angina, Unstable; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptides; Dipept | 2013 |
Saxagliptin, alogliptin, and cardiovascular outcomes.
Topics: Adamantane; Angina, Unstable; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptides; Dipept | 2014 |
Saxagliptin, alogliptin, and cardiovascular outcomes.
Topics: Angina, Unstable; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Hyp | 2014 |
Gliptins - do they increase cardiovascular risk or benefit?
Topics: Adamantane; Angina, Unstable; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptides; Dipept | 2014 |
[New antihyperglycemic drugs. Examination of cardiovascular outcomes with alogliptin versus standard of care (EXAMINE) and saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus-thrombolysis in myocardial infarction (SAVOR
Topics: Adamantane; Angina, Unstable; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptides; Dipept | 2014 |
Lixisenatide in Type 2 Diabetes and Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Angina, Unstable; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibi | 2016 |